Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Intrauterine Drug Delivery Systems

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

Birth Control Methods

Birth Control Methods

Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although vasectomy...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prevalence of endometrial hyperplasia and carcinoma in women with polycystic ovarian syndrome.

F&S reports·2025

Same author

Letters to the Editor.

Menopause (New York, N.Y.)·2025

Same author

Comparison of estrogenic components used for hormonal contraception.

Contraception·2023

Same author

Symptom-associated alterations in functional connectivity in primary and secondary provoked vestibulodynia.

Pain·2022

Same author

Does timing matter when initiating elagolix in a natural menstrual cycle?

F&S reports·2021

Same author

Successful Vaginal Delivery after External Cephalic Version in a Woman with a Large Partial Uterine Septum.

Case reports in obstetrics and gynecology·2021

Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Published on: October 11, 2024

Drospirenone/ethinyl estradiol.

Andrea J Rapkin¹, Shelley N Sorger, Sharon A Winer

¹Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, California, USA. arapkin@mednet.ucla.edu

Drugs of Today (Barcelona, Spain : 1998)

|April 5, 2008

Summary

This summary is machine-generated.

This new oral contraceptive combines drospirenone and ethinyl estradiol in a 24/4 regimen. It effectively prevents pregnancy, treats Premenstrual Dysphoric Disorder (PMDD), and improves moderate acne.

More Related Videos

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model

Published on: August 11, 2023

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Published on: November 11, 2022

Related Experiment Videos

Last Updated: Jul 6, 2026

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Published on: October 11, 2024

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model

Published on: August 11, 2023

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care

Published on: November 11, 2022

Area of Science:

Reproductive Health
Endocrinology
Dermatology

Background:

Traditional oral contraceptives offer benefits like cycle regularity but often fail to improve side effects such as weight gain, bloating, and mood alterations, including Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD).
Recent contraceptive research aims to enhance side effect profiles and provide additional noncontraceptive health and lifestyle advantages, supported by evidence-based medicine.

Purpose of the Study:

To evaluate the efficacy and benefits of a novel oral contraceptive formulation containing drospirenone 3 mg/ethinyl estradiol 20 microg in a 24/4 dosing regimen.
To highlight the unique properties of drospirenone, including its antimineralocorticoid and antiandrogenic effects.

Main Methods:

Utilized a 24-day hormonally active pill regimen followed by 4 days of inactive pills, representing an extended pill regimen.
Conducted large, randomized, controlled trials to assess the contraceptive's efficacy and impact on PMDD and acne vulgaris.

Main Results:

The drospirenone/ethinyl estradiol 24/4 formulation is the only hormonally based contraceptive with demonstrated efficacy for PMDD in large, randomized, controlled trials.
Received U.S. Food and Drug Administration (FDA) approval for pregnancy prevention, PMDD treatment, and moderate acne vulgaris in women seeking oral contraception.

Conclusions:

Drospirenone 3 mg/ethinyl estradiol 20 microg (24/4) offers a unique oral contraceptive option with expanded indications beyond pregnancy prevention.
This formulation addresses common side effects not typically improved by traditional oral contraceptives, including PMDD and moderate acne.